Plasma concentration of fibronectin is decreased in patients with hypertrophic cardiomyopathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10330564" target="_blank" >RIV/00179906:_____/16:10330564 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/16:43875679 RIV/00216208:11150/16:10330564

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.cca.2016.09.024" target="_blank" >http://dx.doi.org/10.1016/j.cca.2016.09.024</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cca.2016.09.024" target="_blank" >10.1016/j.cca.2016.09.024</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Plasma concentration of fibronectin is decreased in patients with hypertrophic cardiomyopathy

Popis výsledku v původním jazyce

To confirm the initial iTRAQ-based proteomic findings related to the plasma fibronectin level and hypertrophic cardiomyopathy using an antibody-based assay. The iTRAQ technique was used for the discovery proteomic analysis of the pooled plasma samples. The ELISA was used for verification of fibronectin plasma concentration in individual samples. Additional five related plasma proteins were assessed: matrix metalloproteinase 2, matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1, tissue inhibitor of metalloproteinase 2 and brain natriuretic peptide. The plasma fibronectin level in patients with hypertrophic cardiomyopathy was significantly lower in comparison to the healthy subjects [215.5+-47.3μg/ml, n=17 vs. 376.7+-134.8μg/ml, n=17; p<0.0001]. In this study we present and confirm our initial proteomic findings and we suggest fibronectin as a potential indicator of an extracellular matrix remodeling related to the hypertrophic cardiomyopathy.

Název v anglickém jazyce

Plasma concentration of fibronectin is decreased in patients with hypertrophic cardiomyopathy

Popis výsledku anglicky

To confirm the initial iTRAQ-based proteomic findings related to the plasma fibronectin level and hypertrophic cardiomyopathy using an antibody-based assay. The iTRAQ technique was used for the discovery proteomic analysis of the pooled plasma samples. The ELISA was used for verification of fibronectin plasma concentration in individual samples. Additional five related plasma proteins were assessed: matrix metalloproteinase 2, matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1, tissue inhibitor of metalloproteinase 2 and brain natriuretic peptide. The plasma fibronectin level in patients with hypertrophic cardiomyopathy was significantly lower in comparison to the healthy subjects [215.5+-47.3μg/ml, n=17 vs. 376.7+-134.8μg/ml, n=17; p<0.0001]. In this study we present and confirm our initial proteomic findings and we suggest fibronectin as a potential indicator of an extracellular matrix remodeling related to the hypertrophic cardiomyopathy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13721" target="_blank" >NT13721: Cílená proteomická analýza u hypertrofické kardiomyopatie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinica Chimica Acta

ISSN

0009-8981

e-ISSN

—

Svazek periodika

463

Číslo periodika v rámci svazku

December

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

62-66

Kód UT WoS článku

000390726500012

EID výsledku v databázi Scopus

2-s2.0-84992036598